pan-ErbB inhibitors

The companies are developing an EGFR mutant-selective inhibitor with a companion diagnostic that will select NSCLC patients with an EGFR mutation linked to resistance to drugs like Iressa and Tarceva.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.